US Department of Defense grants Prenosis up to $ 4.3 million to improve early identification of sepsis in combatants using predictive point-of-care diagnostics


CHICAGO, November 17, 2021 / PRNewswire / – Prenosis, Inc., a precision diagnostics company transforming clinical diagnostics with predictive intelligence, today announced that the Defense Threat Reduction Agency (DTRA), a US Department of Defense agency that tackles emerging threats, awarded the company up to $ 4.3 million for the further development of point-of-care technology for the early detection of sepsis in combatants in the field.

Fighters in the field can often be exposed to infections, which can quickly lead to life-threatening complications, including sepsis. It is currently difficult to identify the combatants most at risk of sepsis, due both to the usual lack of practical access to a centralized clinical laboratory and to the lack of precise diagnoses of sepsis in general. Quick and accurate identification of fighters most likely to deteriorate from sepsis could allow for earlier medical evacuations and life-saving treatment. The risk of death from sepsis has been reported to increase by 8% per hour without treatment[1], stressing the need to identify and treat these cases as early as possible.

Prenosis developed its Immunixâ„¢ Emergency point of service (ePOC) system to meet this critical need.

The Immunixâ„¢ The ePOC system is one of Prenosis’s advanced platforms for predictive and precision diagnostics, or prenostics, which seeks to predict disease more accurately and cost effectively.

“We are delighted to partner with DTRA and that the agency has recognized the potential impact of our Immunixâ„¢ Emergency service point system on our front lines, ”said Bobby Reddy, Jr., CEO and co-founder of Prenosis. “Our point-of-care solution has the potential to help provide accurate and early detection of sepsis in frontline combatants, and could also improve pre-hospital identification of sepsis in civilian communities. “

The Immunixâ„¢ The ePOC system builds on Immunix from Prenosisâ„¢ platform, which uses machine learning algorithms harnessing a wide variety of biological and clinical data designed to holistically identify sepsis as early as possible in hospital environments. In this project, Prenosis will adapt the Immunixâ„¢ platform for the detection of sepsis in the combatant population at the point of care by replacing the use of large standard clinical laboratory analyzers with a mobile system. To develop the hardware elements of the project, Prenosis will contract with immune testing company Kypha Inc. Prenosis has licensed Kypha’s RapiPlex reader and multiplex cartridge technology platform to rapidly deliver data for its proprietary algorithms developed. field service.

The ePOC system includes the new ImmunoScan from Prenosisâ„¢ point-of-service technology, wearable devices and a core mobile application linked to NOSIS, owned by Prenosisâ„¢ dataset, one of the largest biomarker-clinical hybrid datasets ever created for sepsis.

According to the World Health Organization, more than 11 million people die from sepsis each year worldwide, more than the deaths from all cancers combined. Studies show sepsis is the leading cause of death in US hospitals with estimated annual treatment and rehabilitation costs of $ 62 billion.[2] Before the COVID-19 pandemic, at least 1.7 million adults in United States developed sepsis. During the pandemic, this problem was dramatically exacerbated, as most deaths from COVID-19 are due to viral and / or bacterial sepsis.[3]

About Prenose
Prenosis is a healthcare technology innovator dedicated to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its Immunixâ„¢ The precision diagnostic platform is powered by machine learning algorithms trained on deep biological data and vast clinical data designed to more holistically capture and illuminate complex patient health conditions. Its owner NOSISâ„¢ The dataset is one of the largest and fastest growing hybrid clinical and biomarker datasets for sepsis care. Sepsis ImmunoScoreâ„¢ diagnosis on Immunixâ„¢ The platform has the potential to save thousands of lives and billions of dollars in healthcare spending every year. Sepsis ImmunoScoreâ„¢ is not yet approved for commercial use in the United States.

More information:

[1] Kumar A et al. The duration of hypotension before the initiation of effective antimicrobial therapy is the essential determinant of survival in human septic shock. Intensive care medicine. 2006; (34): 1589-1596.

[2] Buchman, Timothy G. PhD, MD, et al, Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012-2018 *, Critical Care Medicine: march 2020 – Volume 48 – Number 3 – p 276-288 doi: 10.1097 / CCM.0000000000004224

[3] Karakike, Eleni MD, et al, Coronavirus disease 2019 as a cause of viral sepsis, critical care medicine: July 12, 2021 – Volume – Number – doi: 10.1097 / CCM.00000000000005195

SOURCE Prenosis

Related links


Comments are closed.